Results 351 to 360 of about 3,292,689 (405)
Some of the next articles are maybe not open access.
Nonfunctioning Pituitary Tumors and Pituitary Incidentalomas
Endocrinology and Metabolism Clinics of North America, 2008Clinically nonfunctioning adenomas (CNFAs) range from being completely asymptomatic, and therefore detected at autopsy or as incidental findings on head MRI or CT scans performed for other reasons, to causing significant hypothalamic/pituitary dysfunction and visual field compromise because of their large size.
openaire +2 more sources
Anti-Cancer Drugs, 1992
This article reviews the current general approach to the biochemical diagnosis and the treatment of pituitary tumors with special reference to medical treatment with dopamine agonists and somatostatin analogs. Dopamine agonists are the treatment of choice in patients with prolactin producing tumors.
openaire +2 more sources
This article reviews the current general approach to the biochemical diagnosis and the treatment of pituitary tumors with special reference to medical treatment with dopamine agonists and somatostatin analogs. Dopamine agonists are the treatment of choice in patients with prolactin producing tumors.
openaire +2 more sources
Overview of the 2022 WHO Classification of Pituitary Tumors
Endocrine pathology, 2022S. Asa, O. Mete, A. Perry, R. Osamura
semanticscholar +1 more source
2017
Pituitary adenomas are among the most common intracranial tumors. The vast majority of these lesions are benign; however, many will require treatment due to local mass effect or hormone oversecretion. This chapter discusses the natural history, presentation, workup, and management of pituitary adenomas.
Toral R. Patel, Viviane S. Tabar
openaire +1 more source
Pituitary adenomas are among the most common intracranial tumors. The vast majority of these lesions are benign; however, many will require treatment due to local mass effect or hormone oversecretion. This chapter discusses the natural history, presentation, workup, and management of pituitary adenomas.
Toral R. Patel, Viviane S. Tabar
openaire +1 more source
mTOR promotes pituitary tumor development through activation of PTTG1
Oncogene, 2017Rongrong Chen +12 more
semanticscholar +1 more source
Brain and other central nervous system tumor statistics, 2021
Ca-A Cancer Journal for Clinicians, 2021Kimberly D Miller +2 more
exaly
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Paolo Tarantino +2 more
exaly